Pages that link to "Q36445966"
Jump to navigation
Jump to search
The following pages link to Chemotherapy and targeted therapy combinations in advanced melanoma (Q36445966):
Displaying 50 items.
- RETRACTED ARTICLE: Non-thermal Plasma Induces Apoptosis in Melanoma Cells via Production of Intracellular Reactive Oxygen Species (Q33448422) (← links)
- Induction of thyroid gene expression and radioiodine uptake in melanoma cells: novel therapeutic implications (Q33480990) (← links)
- The Role of B-RAF Mutations in Melanoma and the Induction of EMT via Dysregulation of the NF-κB/Snail/RKIP/PTEN Circuit (Q34106285) (← links)
- Unexpected high response rate to traditional therapy after dendritic cell-based vaccine in advanced melanoma: update of clinical outcome and subgroup analysis (Q34170003) (← links)
- P-Rex1 is required for efficient melanoblast migration and melanoma metastasis (Q34235334) (← links)
- Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance (Q34307356) (← links)
- Design, synthesis, and biological evaluation of N-acetyl-S-(p-chlorophenylcarbamoyl)cysteine and its analogs as a novel class of anticancer agents (Q34520444) (← links)
- The dual RAF/MEK inhibitor CH5126766/RO5126766 may be a potential therapy for RAS-mutated tumor cells (Q34572036) (← links)
- Molecular determinants of melanoma malignancy: selecting targets for improved efficacy of chemotherapy (Q35118157) (← links)
- Sorafenib and dacarbazine as first-line therapy for advanced melanoma: phase I and open-label phase II studies (Q35212678) (← links)
- Biomarkers as key contributors in treating malignant melanoma metastases (Q35550888) (← links)
- Systematic review of medical treatment in melanoma: current status and future prospects. (Q35584299) (← links)
- Synthesis and biological evaluation of benzo[d][1,3]dioxol-5-yl chalcones as antiproliferating agents (Q35648976) (← links)
- Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health (Q35679353) (← links)
- Inhibition of Ras for Cancer Treatment: The Search Continues (Q35944601) (← links)
- Targeting drivers of melanoma with synthetic small molecules and phytochemicals (Q36141097) (← links)
- DW-F5: A novel formulation against malignant melanoma from Wrightia tinctoria (Q36293476) (← links)
- Prospective multicenter phase II trial of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with advanced extremity melanoma (Q36343055) (← links)
- Therapeutic targets in melanoma: map kinase pathway (Q36562233) (← links)
- Melanoma biology and new targeted therapy (Q36742015) (← links)
- New approaches in metastatic melanoma: biological and molecular targeted therapies (Q36817127) (← links)
- Sorafenib-induced eruptive melanocytic lesions. (Q36914911) (← links)
- Melanocyte receptors: clinical implications and therapeutic relevance. (Q36954814) (← links)
- Recent discoveries in the genetics of melanoma and their therapeutic implications (Q37024839) (← links)
- MDM4 is a key therapeutic target in cutaneous melanoma (Q37096987) (← links)
- Targeting the RAS pathway in melanoma (Q37137004) (← links)
- Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy (Q37286893) (← links)
- The RAS/mitogen activated protein (MAP) kinase pathway in melanoma biology and therapeutics (Q37290440) (← links)
- Evaluation of (68)Ga- and (177)Lu-DOTA-PEG4-LLP2A for VLA-4-Targeted PET Imaging and Treatment of Metastatic Melanoma (Q37515861) (← links)
- Small molecules and targeted therapies in distant metastatic disease. (Q37555793) (← links)
- High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. (Q37635287) (← links)
- Targeting the MAPK pathway in melanoma: why some approaches succeed and other fail (Q37745182) (← links)
- A new era: melanoma genetics and therapeutics (Q37815139) (← links)
- Head and neck mucosal malignant melanoma: clinicopathologic correlation with contemporary review of prognostic indicators (Q37921515) (← links)
- Emerging molecular targets in melanoma invasion and metastasis (Q38055272) (← links)
- Advances in personalized targeted treatment of metastatic melanoma and non-invasive tumor monitoring (Q38091649) (← links)
- Protein kinase inhibitors in melanoma (Q38132900) (← links)
- Current research and development of chemotherapeutic agents for melanoma (Q38166569) (← links)
- Systemic therapy of non-resectable metastatic melanoma (Q38166572) (← links)
- Combined activity of temozolomide and the mTOR inhibitor temsirolimus in metastatic melanoma involves DKK1. (Q38830266) (← links)
- Targeting c-Met in melanoma: mechanism of resistance and efficacy of novel combinatorial inhibitor therapy (Q38986202) (← links)
- Glutamatergic Pathway Targeting in Melanoma: Single-Agent and Combinatorial Therapies (Q39168954) (← links)
- RSK promotes G2 DNA damage checkpoint silencing and participates in melanoma chemoresistance (Q39251898) (← links)
- The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells (Q39644498) (← links)
- Caspase-3 cleaves XIAP in a positive feedback loop to sensitize melanoma cells to TRAIL-induced apoptosis (Q39653516) (← links)
- Braf(V600E) cooperates with Pten loss to induce metastatic melanoma (Q39873596) (← links)
- Inhibition of PI3K-AKT-mTOR signaling sensitizes melanoma cells to cisplatin and temozolomide (Q39905603) (← links)
- Notch1 is an effector of Akt and hypoxia in melanoma development (Q39928689) (← links)
- Combined inhibition of MAPK and mTOR signaling inhibits growth, induces cell death, and abrogates invasive growth of melanoma cells (Q40005203) (← links)
- Toxicity and Immunogenicity in Murine Melanoma following Exposure to Physical Plasma-Derived Oxidants. (Q41067821) (← links)